No record found
No record found
No record found
capitalstake.com. Provided by * Returns not adjusted for payouts
^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.
Company Profile
Abbott Laboratories (Pakistan) Limited is a public limited company incorporated in Pakistan on July 02, 1948. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.
| Syed Anis Ahmed | CEO |
| Ehsan A. Malik | Chairperson |
| Muhammad Usama Jamil | Company Secretary |
Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi, Pakistan
FAMCO Share Registration Services (Pvt) Limited, 8-F, Next to Hotel Faran, Nursery Block 6, P.E.C.H.S, Shahrah-e-Faisal,Karachi
EY Ford Rhodes, Chartered Accountants
December
Equity Profile
Announcements
| Date | Title | Document |
|---|---|---|
| Aug 28, 2026 | Transmission of Quarterly Financial Statements for the Period Ended June 30, 2026 | View PDF |
| Aug 28, 2026 | Financial Results for the Half Year Ended June 30 2026 | View PDF |
| Apr 29, 2026 | Transmission of Quarterly Report for the Period Ended March 31, 2026 | View PDF |
| Apr 27, 2026 | Financial Results for the Quarter Ended March 31, 2026 | View PDF |
| Apr 8, 2026 | Transmission of Annual Report for the Year Ended December 31, 2025 | View PDF |
| Date | Title | Document |
|---|---|---|
| Jun 10, 2026 | Re-Appointment of Chairman | View PDF |
| Jun 10, 2026 | Re-Appointment of Chief Executive Officer | View PDF |
| Jun 2, 2026 | Dissemination of Video Recording Link of Corporate Briefing Session (CBS) 2026 | View PDF |
| May 25, 2026 | Revised Presentation of Corporate Briefing Session 2026 | View PDF |
| May 22, 2026 | Presentation of Corporate Briefing Session 2026 | View PDF |
Financials
All numbers in thousands (000's) except EPS
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 75,397,732 | 68,177,197 | 55,475,270 | 49,257,722 |
| Profit after Taxation | 7,966,500 | 5,234,233 | 261,777 | 3,004,186 |
| EPS | 81.37 | 53.46 | 2.67 | 30.69 |
| Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|
| Sales | 17,704,722 | 19,819,134 | 19,061,338 | 17,346,451 |
| Profit after Taxation | 1,940,308 | 1,822,546 | 1,943,499 | 1,599,673 |
| EPS | 19.82 | 18.62 | 19.85 | 16.34 |

Ratios
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Gross Profit Margin (%) | 35.08 | 28.95 | 21.36 | 29.49 |
| Net Profit Margin (%) | 10.57 | 7.68 | 0.47 | 6.10 |
| EPS Growth (%) | 52.21 | 1,902.25 | (91.30) | (49.65) |
| PEG | 0.25 | 0.01 | (1.89) | (0.30) |









Feedback
Terms of Use
https://www.psx.com.pk